X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ACTAVIS (US) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ACTAVIS
EQUITY SHARE DATA
    NOVARTIS
Mar-17
ACTAVIS
Dec-14
NOVARTIS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs85518,553-   
Low Rs66611,317-   
Sales per share (Unadj.) Rs219.03,340.9-  
Earnings per share (Unadj.) Rs19.1-416.9-  
Cash flow per share (Unadj.) Rs20.3306.5-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs307.07,246.3-  
Shares outstanding (eoy) m29.96265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.54.5 77.6%   
Avg P/E ratio x39.8-35.8 -111.1%  
P/CF ratio (eoy) x37.548.7 76.9%  
Price / Book Value ratio x2.52.1 120.2%  
Dividend payout %52.40-   
Avg Mkt Cap Rs m22,7793,971,215 0.6%   
No. of employees `0000.721.6 3.1%   
Total wages/salary Rs m1,3930-   
Avg. sales/employee Rs Th9,736.241,127.2 23.7%   
Avg. wages/employee Rs Th2,066.80-   
Avg. net profit/employee Rs Th849.0-5,132.2 -16.5%   
INCOME DATA
Net Sales Rs m6,562888,347 0.7%  
Other income Rs m702-2,217 -31.6%   
Total revenues Rs m7,264886,129 0.8%   
Gross profit Rs m259114,121 0.2%  
Depreciation Rs m36192,359 0.0%   
Interest Rs m728,020 0.0%   
Profit before tax Rs m917-108,476 -0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,957 0.0%   
Tax Rs m345-5,577 -6.2%   
Profit after tax Rs m572-110,856 -0.5%  
Gross profit margin %3.912.8 30.7%  
Effective tax rate %37.65.1 731.8%   
Net profit margin %8.7-12.5 -69.9%  
BALANCE SHEET DATA
Current assets Rs m9,731468,045 2.1%   
Current liabilities Rs m1,830341,342 0.5%   
Net working cap to sales %120.414.3 844.2%  
Current ratio x5.31.4 387.7%  
Inventory Days Days4958 83.9%  
Debtors Days Days2566 38.0%  
Net fixed assets Rs m57108,476 0.1%   
Share capital Rs m1410-   
"Free" reserves Rs m9,0560-   
Net worth Rs m9,1961,926,791 0.5%   
Long term debt Rs m01,009,676 0.0%   
Total assets Rs m11,4993,531,174 0.3%  
Interest coverage x128.4-2.9 -4,471.8%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.3 226.8%   
Return on assets %5.0-2.3 -214.8%  
Return on equity %6.2-5.8 -108.1%  
Return on capital %10.1-3.0 -333.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,6050-   
CASH FLOW
From Operations Rs m-380152,546 -0.2%  
From Investments Rs m4,208-365,255 -1.2%  
From Financial Activity Rs m-3,318205,220 -1.6%  
Net Cashflow Rs m510-7,488 -6.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.01 Rs / USD

Compare NOVARTIS With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: ABBOTT INDIA  FDC LTD.  BIOCON LTD  IPCA LABS  PFIZER  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 19, 2018 03:37 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS